EPO906 Therapy in Patients With Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

May 31, 2003

Conditions
Melanoma
Interventions
DRUG

epothilone b

intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off

Trial Locations (6)

15213

UPMC Health Systems, Pittsburgh

27710

Duke University Medical Center, Durham

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

74104

Oklahoma Oncology, Inc., Tulsa

80045

University of Colorado, Aurora

10466-2697

Comprehensive Cancer Center@ Our Lady if Mercy Medical Center, The Bronx

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY